You are here

Seagen

Biopharma stocks go back to bleak

EP Vantage

Thu, 04/6/23 - 09:51 am

Apellis Pharmaceuticals

Protagonist Therapeutics

Reata Pharmaceuticals

FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer

BioSpace

Tue, 04/4/23 - 12:35 pm

metastatic urothelial carcinoma

Disgraced former Seagen CEO tapped to lead MorphImmune less than a year after domestic assault arrest

Fierce Biotech

Thu, 03/23/23 - 11:51 am

Purdue University

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

BioPharma Dive

Tue, 03/14/23 - 06:28 pm

anticompetitive practices

Pfizer CEO points to IRA as a factor that made Seagen an attractive target

Endpoints

Tue, 03/14/23 - 11:00 am

Inflation Reduction Act

Pfizer to buy Seagen in $43B cancer drug deal

BioPharma Dive

Mon, 03/13/23 - 10:57 am

Pfizer Is Targeting an Acquisition That Could Be a Game Changer for Its Business

Motley Fool

Thu, 03/9/23 - 11:28 am

Seagen has a New Suitor as Pfizer Talks Begin

BioSpace

Mon, 02/27/23 - 10:21 am

Daiichi Sankyo gets US patent office to restart review of Seagen patent

Endpoints

Mon, 02/20/23 - 12:40 pm

Seagen mum on Merck buyout rumors as it bats for blockbuster with Adcetris

BioSpace

Thu, 02/16/23 - 11:27 am

ASCO-GU – Bicycle tries to put distance between itself and Seagen

EP Vantage

Thu, 02/16/23 - 10:15 am

Bicycle Therapeutics

urothelial cancer

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Fierce Biotech

Mon, 02/13/23 - 10:29 am

Corbus Pharmaceuticals

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

RAPS.org

Sun, 01/22/23 - 01:00 pm

clinical trials

clinicaltrials.gov

Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Endpoints

Mon, 12/12/22 - 10:39 pm

Hodgkin's lymphoma

Seagen's highest selling drug snags a label expansion for pediatric cancer patients

Endpoints

Sun, 11/13/22 - 07:01 pm

Hodgkin's lymphoma

In transition and tumult, Seagen names former Novartis oncology chief Epstein as new CEO

Fierce Pharma

Thu, 11/10/22 - 10:52 am

Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug

BioPharma Dive

Mon, 09/26/22 - 11:20 pm

Lava Therapeutics

bispecific antibodies

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

Endpoints

Mon, 09/19/22 - 10:02 pm

ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

Fierce Pharma

Thu, 09/8/22 - 04:40 pm

urothelial cancer

Merck's Deal With Seagen May Have Fallen Through. Now What?

Motley Fool

Wed, 09/7/22 - 10:16 am

Pages